In the top alliance by deal value, AbbVie and Xilio Therapeutics entered a collaboration and option-to-license agreement to develop up to four novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers.
The partnership will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?